Melatonin 2 receptor Inhibitors
1 drugsAbout Melatonin 2 receptor
The Melatonin 2 receptor (MT2) is a G protein-coupled receptor that binds melatonin, regulating sleep-wake cycles. It is a target of interest in drug development due to its role in various physiological processes.
Currently, there is no genetic evidence available linking the MT2 receptor to specific diseases. However, the existence of an approved drug suggests potential therapeutic benefits that warrant further investigation.
The MT2 receptor is targeted by one FDA-approved drug, TEPMETKO, a small molecule developed by EMD SERONO INC. It is categorized under 'Other' therapeutic areas.
Top Melatonin 2 receptor Drugs
EMD SERONO INC is the only company with an approved drug targeting the Melatonin 2 receptor.
The market is not competitive, so new entrants may face fewer barriers.
Melatonin 2 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Melatonin 2 receptor, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Melatonin 2 receptor Clinical Trials 21 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Melatonin 2 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 13 | 8 | 2 | 3 | 80% |
| Phase 2 | 7 | 1 | 1 | 5 | 50% |
| Phase 3 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Melatonin 2 receptor Drug Approval Timeline (2021 - 2021)
Metastatic non-small cell lung cancer (NSCLC) harboring m...
The first and most recent drug approval for the MT2 receptor was TEPMETKO in 2021.
The recent approval suggests renewed interest, but further approvals are needed to confirm a positive trend.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 12 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Melatonin 2 receptor. A trial counts if an approved drug acting on Melatonin 2 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.